MYH8, Blocking Peptide

Myosin heavy chain 8; Myosin-8; Myosin heavy chain skeletal muscle perinatal; MyHC-perinatal; MyHC-peri; MyHC-pn; gtMHC-F; myosin, heavy chain 8, skeletal muscle, perinatal

For Research Use Only. Not for use in diagnostic procedures.

Liquid

200 ug/mL (lot specific)

Store MYH8 peptide at -20 degree C, stable for one year.

Small volumes of MYH8 blocking peptide vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Blocking (BL)

MYH8 peptide is used for blocking the activity of MYH8 antibody.

222,763 Da

myosin, heavy chain 8, skeletal muscle, perinatal

myosin-8; myHC-perinatal; myosin heavy chain 8; fetal-myosin heavy chain; myosin heavy chain, skeletal muscle, perinatal; myosin, heavy polypeptide 8, skeletal muscle, perinatal

Myosin-8

MyHC-perinatal  [Similar Products]

MYH8_HUMAN

Myosins are actin-based motor proteins that function in the generation of mechanical force in eukaryotic cells. Muscle myosins are heterohexamers composed of 2 myosin heavy chains and 2 pairs of nonidentical myosin light chains. This gene encodes a member of the class II or conventional myosin heavy chains, and functions in skeletal muscle contraction. This gene is predominantly expressed in fetal skeletal muscle. This gene is found in a cluster of myosin heavy chain genes on chromosome 17. A mutation in this gene results in trismus-pseudocamptodactyly syndrome. [provided by RefSeq, Sep 2009]

MYH8: Muscle contraction. Defects in MYH8 are a cause of Carney complex variant (CACOV). Carney complex is a multiple neoplasia syndrome characterized by spotty skin pigmentation, cardiac and other myxomas, endocrine tumors, and psammomatous melanotic schwannomas. Familial cardiac myxomas are associated with spotty pigmentation of the skin and other phenotypes, including primary pigmented nodular adrenocortical dysplasia, extracardiac (frequently cutaneous) myxomas, schwannomas, and pituitary, thyroid, testicular, bone, ovarian, and breast tumors. Cardiac myxomas do not develop in all patients with the Carney complex, but affected patients have at least two features of the complex or one feature and a clinically significant family history. Defects in MYH8 are a cause of distal arthrogryposis type (DA7). A hereditary distal arthrogryposis characterized by an inability to open the mouth fully (trismus) and pseudocamptodactyly in which wrist dorsiflexion, but not volarflexion, produces involuntary flexion contracture of distal and proximal interphalangeal joints. Such hand and jaw contractures are caused by shortened flexor muscle-tendon units. Similar lower-limb contractures also produce foot deformity. The trismus-pseudocamptodactyly syndrome is a morbid autosomal dominant trait with variable expressivity but high penetrance. In these patients, trismus complicates dental care, feeding during infancy, and intubation for anesthesia, and the pseudocamptodactyly impairs manual dexterity, with consequent occupational and social disability. Many patients require surgical correction of contractures.

Protein type: Motor; Motility/polarity/chemotaxis

Chromosomal Location of Human Ortholog: 17p13.1

Cellular Component: sarcomere; cytoplasm; muscle myosin complex; cytosol

Molecular Function: actin filament binding; calmodulin binding; microfilament motor activity; structural constituent of muscle; ATPase activity; myosin light chain binding; ATP binding

Biological Process: skeletal muscle contraction; muscle contraction; metabolic process; muscle filament sliding

Disease: Carney Complex Variant; Arthrogryposis, Distal, Type 7

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.